clinical trial

July 2, 2015July 2, 2015

RedHill Biopharma Issued Key US Patents for Promising Crohn’s Disease Treatment Candidate

Crohn's Disease, News

Israel-based biopharmaceutical company RedHill Biopharma Ltd. recently announced its acquisition of two notices of allowance from the United States Patent and Trademark Office (USPTO) covering patient application numbers 13/722,395 and 14/271,758 for RHB-104, ... Read more

February 20, 2015February 20, 2015

Oncobiologics Announces Successful Clinical Trial for IBD Treatment

IBD News, News

Biopharmaceutical company Oncobiologics, Inc. recently announced that its product ONS-3010, an adalimumab (Humira®) biosimilar candidate, has met the primary endpoints in its first clinical trial. ONS-3010 was developed as a biosimilar of adalimumab, ... Read more

February 11, 2015February 12, 2015

Second Genome’s New IBD Drug Advances To Phase 1 Trial

IBD News, News

Second Genome Inc. recently advanced SGM-1019, the company’s primary microbiome drug indicated for inflammatory bowel disease (IBD), to Phase 1 clinical testing to identify an optimal dose. Peter DiLaura, President and the CEO of the company, said ... Read more

December 5, 2014December 5, 2014

TxCell Enrolls First Patient for Phase IIb Crohn’s Disease Study

News

TxCell SA, a biotechnology company specializing in developing novel immunotherapies for severe chronic inflammatory and autoimmune diseases, has just announced the enrollment and dosing of the first patient in the ... Read more

October 31, 2014October 31, 2014

FDA Endorses Further Studies on Ulcerative Colitis Drug from Lipid Therapeutics

News, Ulcerative colitis

Biopharmaceutical company Lipid Therapeutics has just announced the successful enrollment of the first batch of participants in a Phase III clinical trial for LT-02, the company’s first-in-class highly purified phosphatidylcholine pipeline product indicated for ... Read more

September 22, 2014September 22, 2014

Phase II Trial for Bertilimumab for Ulcerative Colitis Launched

IBD News, News, Ulcerative colitis

Massachusetts-based Immune Pharmaceuticals Inc., a company that specializes in creating antibody therapeutics for chronic inflammatory conditions, recently announced the start of participant screening for its Phase II clinical trial of one of ... Read more